Early statin use after type 2 diabetes diagnosis linked to 15% lower dementia risk

MUNICH - Adults who started a cholesterol-lowering statin soon after a type 2 diabetes diagnosis had a lower risk of dementia over the next decade than peers who never started one within five years, according to research presented at the European Society of Cardiology Congress and covered by Fox News.

Danish investigators followed 132,585 people who developed type 2 diabetes from 2006 through 2019 and had no prior statin use or dementia. Results were published in The Lancet Regional Health Europe. Over a median 7.1 years of follow-up, 2.7% developed dementia.

Compared with no statin within five years of diagnosis, starting within one year was linked to a 15% lower relative risk of dementia at 10 years. Starting between one and five years was linked to a 10% lower relative risk. Estimated absolute 10-year dementia risks were 3.9% with no statin, 3.3% with early start and 3.5% with later start. Results were similar in women and men.

Dr. Liron Sinvani, a geriatrician at Northwell Institute for Healthy Aging in New York, told Fox News Digital the study was large and well designed. She said the benefit appeared driven more by lower vascular dementia risk than Alzheimer's disease, which fits how statins protect blood vessels and reduce inflammation.

Lead researchers noted that many people with type 2 diabetes still do not get timely statin therapy despite proven heart benefits. They said the dementia findings add another reason to discuss early treatment when LDL cholesterol is high after a diabetes diagnosis.

The study is observational. It cannot prove that statins alone prevent dementia. People should not start or stop medicine based on this report without medical advice. Side effects, liver tests, muscle symptoms and drug interactions still matter. For adults managing diabetes, the practical step is a clear conversation with a clinician about cholesterol targets, statin timing and overall brain and heart risk.